ANALYSIS: Has Boston finally turned the corner?
This article was originally published in Clinica
Executive Summary
The headline figures for Boston Scientific's fourth fiscal quarter weren't great: Q4 sales fell 1% to $1.8 billion, while net income almost halved to $60 million. Full-year results told a similar story, with revenues down 5% to $7.2 billion, while the firm swung to a net loss of $4.1 billion (www.clinica.co.uk, 29 January 2013).